ReviewGland surgery2014
Management of recurrent epithelial ovarian cancer.
Review in Gland surgery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Additive value of whole abdomen FDG PET/MRI to standard whole body PET/CT for detection of peritoneal recurrence of ovarian cancer.Journal of ovarian research · 2026Article
- Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report.World journal of clinical cases · 2024Article
- Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer.The oncologist · 2023Article
- SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis.Journal of gynecologic oncology · 2022Article
- IL-6 secretion of CD4Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Role of MALAT1 in gynecological cancers: Pathologic and therapeutic aspects.Oncology letters · 2021Review
- PLGA nanoparticles delivering CPT-11 combined with focused ultrasound inhibit platinum resistant ovarian cancer.Translational cancer research · 2021Article
- miR-26b regulates cell proliferation and apoptosis of CD117+CD44+ ovarian cancer stem cells by targeting PTEN.European journal of histochemistry : EJH · 2021Article
- Research Progress on the Functions and Mechanism of circRNA in Cisplatin Resistance in Tumors.Frontiers in pharmacology · 2021Review
- LNC00115 Mediates Cisplatin Resistance by Regulating the miR-7/ERK Signalling Pathway in Ovarian Cancer.Cancer management and research · 2021Article
- Autophagy-related long non-coding RNA signature for ovarian cancer.The Journal of international medical research · 2020Article
- Stereotactic body radiation therapy in the treatment of ovarian cancer.Radiation oncology (London, England) · 2020Article
- UBE2N Regulates Paclitaxel Sensitivity of Ovarian Cancer via Fos/P53 Axis.OncoTargets and therapy · 2020Article
- The overexpression of lncRNA MEG3 inhibits cell viability and invasion and promotes apoptosis in ovarian cancer by sponging miR-205-5p.International journal of clinical and experimental pathology · 2020Article
- miR-454 suppresses the proliferation and invasion of ovarian cancer by targeting E2F6.Cancer cell international · 2020Article
- Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression.Molecular therapy. Nucleic acids · 2019Article
- lncRNA ABHD11-AS1, regulated by the EGFR pathway, contributes to the ovarian cancer tumorigenesis by epigenetically suppressing TIMP2.Cancer medicine · 2019Article
- MicroRNA-331-3p inhibits proliferation and metastasis of ovarian cancer by targeting RCC2.Archives of medical science : AMS · 2019Article
- Kinase Inhibitors and Ovarian Cancer.Cancers · 2019Review
- lncRNA UCA1 Mediates Resistance to Cisplatin by Regulating the miR-143/FOSL2-Signaling Pathway in Ovarian Cancer.Molecular therapy. Nucleic acids · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer is the fifth most common cancer in women. It is usually diagnosed at an advanced stage and is the leading cause of death from gynecologic cancers in women. The overall survival rate at five years is 50% and its treatment is still poor. We need new treatments for patients with recurrent ovarian cancer who are incurable with current management. We review the effectiveness of new biological agents and morbidity and mortality of cytoreductive surgery. Since the hyperthermic increases the effectiveness of chemotherapy and the chance of survival, hyperthermic intraperitoneal chemotherapy has been proven to be a promising option, however it still requires further study to be the standard treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.